Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo

The flavolignan silibinin was studied for its ability to restore drug sensitivity to EGFR-mutant NSCLC xenografts with epithelial-to-mesenchymal transition (EMT)-driven resistance to erlotinib. As a single agent, silibinin significantly decreased the tumor volumes of erlotinib-refractory NSCLC xenog...

Descripción completa

Detalles Bibliográficos
Autores principales: Cufí, Sílvia, Bonavia, Rosa, Vazquez-Martin, Alejandro, Oliveras-Ferraros, Cristina, Corominas-Faja, Bruna, Cuyàs, Elisabet, Martin-Castillo, Begoña, Barrajón-Catalán, Enrique, Visa, Joana, Segura-Carretero, Antonio, Joven, Jorge, Bosch-Barrera, Joaquim, Micol, Vicente, Menendez, Javier A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748425/
https://www.ncbi.nlm.nih.gov/pubmed/23963283
http://dx.doi.org/10.1038/srep02459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748425/
https://www.ncbi.nlm.nih.gov/pubmed/23963283
http://dx.doi.org/10.1038/srep02459

Ejemplares similares